Compare PBR & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBR | PFE |
|---|---|---|
| Founded | 1953 | 1849 |
| Country | Brazil | United States |
| Employees | 50687 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.7B | 147.6B |
| IPO Year | N/A | 2013 |
| Metric | PBR | PFE |
|---|---|---|
| Price | $16.29 | $24.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $17.56 | ★ $29.29 |
| AVG Volume (30 Days) | 14.2M | ★ 32.6M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | 3.31% | ★ 6.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | ★ $62,579,000,000.00 |
| Revenue This Year | $18.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $13.55 | $50.29 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.43 | $23.11 |
| 52 Week High | $22.24 | $28.75 |
| Indicator | PBR | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 26.55 | 33.34 |
| Support Level | $11.49 | $24.02 |
| Resistance Level | $18.51 | $26.42 |
| Average True Range (ATR) | 0.38 | 0.56 |
| MACD | -0.06 | -0.20 |
| Stochastic Oscillator | 3.67 | 17.25 |
Petrobras is a Brazil-based integrated energy company controlled by the Brazilian government. The company focuses on the exploration and production of oil and gas in Brazilian offshore fields. Production in 2025 was 3.0 million barrels of oil equivalent per day (80% oil), and reserves stood at 12.1 billion boe (84% oil). At the end of 2025, Petrobras operated 10 refineries in Brazil with a capacity of 1.8 million barrels per day and distributed refined products and natural gas throughout the country.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.